Literature DB >> 25283312

Serum HBV surface antigen positivity is associated with low prevalence of metabolic syndrome in Korean adult men.

Ja Sung Choi1, Ki Jun Han, Sangheun Lee, Song Wook Chun, Dae Jung Kim, Hyeon Chang Kim, Hee Man Kim.   

Abstract

BACKGROUND: Metabolic syndrome has clinical implications for chronic liver disease, but the relationship between chronic hepatitis B and metabolic syndrome remains unclear. The aim of this study was to determine whether hepatitis B surface antigen (HBsAg) positivity is associated with metabolic syndrome.
METHODS: Data were obtained from the Third Korean National Health and Nutrition Examination Survey (KNHANES). Participant sera were tested for HBsAg. Metabolic syndrome was defined according to the modified National Cholesterol Education Program Adult Treatment Panel III guidelines for Koreans.
RESULTS: Of the 5108 participants, 209 (4.1%) tested positive for HBsAg, and 1364 (26.7%) were diagnosed with metabolic syndrome. The prevalence of metabolic syndrome was 23.4% in HBsAg-positive men, 31.5% in HBsAg-negative men, 18.6% in HBsAg-positive women, and 23.7% in HBsAg-negative women. After adjusting for multiple factors, male participants who tested positive for serum HBsAg had an odds ratio of 0.612 (95% confidence interval [CI] 0.375-0.998) for metabolic syndrome and an odds ratio of 0.631 (95% CI 0.404-0.986) for elevated triglycerides. Women who tested positive for serum HBsAg had an odds ratio of 0.343 (95% CI 0.170-0.693) for elevated triglycerides.
CONCLUSIONS: Positive results for serum HBsAg are inversely associated with metabolic syndrome in men and with elevated triglycerides in men and women. This suggests that elevated triglycerides may contribute to the inverse association between HBsAg and metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25283312      PMCID: PMC4275441          DOI: 10.2188/jea.JE20140053

Source DB:  PubMed          Journal:  J Epidemiol        ISSN: 0917-5040            Impact factor:   3.211


INTRODUCTION

Chronic hepatitis B, which results from hepatitis B virus (HBV) infection, is widespread in Korea. In 2009, the prevalence of hepatitis B surface antigen (HBsAg), a marker of HBV infection, was 3.2% in Korea.[1] Chronic HBV infection can lead to the development of liver cirrhosis and/or hepatocellular carcinoma.[2] The majority of chronic HBV infections in Korea are acquired in the perinatal period, though some HBV infections are acquired via horizontal transmission. Metabolic syndrome, also known as insulin resistance syndrome, is a constellation of metabolic disorders, including increased waist circumference, hyperglycemia, elevated blood pressure, and an abnormal lipid profile. In Korea, the prevalence of metabolic syndrome has increased markedly in recent years, from 24.9% in 1998 to 31.3% in 2007.[3] Metabolic syndrome is associated with liver diseases, including non-alcoholic fatty liver disease, chronic hepatitis C virus (HCV) infection, and hepatocellular carcinoma. Non-alcoholic fatty liver disease is a hepatic manifestation of metabolic syndrome.[4] In chronic hepatitis C, metabolic syndrome is a potential independent predictor of liver-related mortality.[5] Insulin resistance reduces the response to anti-HCV treatment.[6] Metabolic syndrome is a possible risk factor for hepatocellular carcinoma, independent of the hepatitis virus.[4],[7] However, to the best of our knowledge, there are few existing studies on the association between metabolic syndrome and chronic hepatitis B. Three studies conducted in Asian populations reported that chronic hepatitis B is associated with a low prevalence of metabolic syndrome.[8]–[10] However, the study populations were limited to small geographic areas, which may have led to selection bias. In addition, the statistical models used in these three studies were not adjusted for all potentially confounding factors. The Third Korean National Health and Nutrition Examination Survey (KNHANES III) is a population-based examination survey conducted in 2005 by the Korean Centers for Disease Control and Prevention and the Korean Ministry of Health and Welfare.[11] KNHANES III was designed to yield data representative of the Korean population. Thus, use of KNHANES III data will hopefully prevent selection bias that may have been unavoidable in the aforementioned studies focused on smaller geographic areas.[8]–[10] HBV is endemic to Korea, and the prevalence of metabolic syndrome is also increasing in Korea.[1],[3] The aim of this study was to use representative data from KNHANES III to investigate the possible association between HBsAg and metabolic syndrome and to determine if there are correlations between HBsAg and components of metabolic syndrome, including elevated blood pressure, elevated blood glucose, elevated triglycerides, low high-density lipoprotein (HDL) cholesterol, or increased waist circumference.

METHODS

Study population and data

The KNHANES III data used in this study included anthropometric measurements, questionnaire responses, and blood chemistry tests. Enrolled participants were ≥20 years of age and underwent an examination including a test for serum HBsAg, which was detected using an electrochemiluminescence immunoassay. A total of 5108 participants were selected and their data analyzed. Approval of this study was obtained from the Institutional Review Board of Myongji Hospital, Goyang, Korea, complying with the Treaty of Helsinki.

Parameters and definitions

Metabolic syndrome was defined based on the modified criteria for Koreans from the National Cholesterol Education Program Adult Treatment Panel III.[12] Participants were categorized into three groups by Korean districts according to the population: large city, small-medium city, or rural area. Subjects with a body mass index ≥25 kg/m2 were considered obese. Increased waist circumference was defined as a waist circumference ≥90 cm in Korean men and ≥85 cm in Korean women.[13] Subjects were considered to have hypertension when systolic blood pressure was ≥140 mm Hg, diastolic blood pressure was ≥90 mm Hg, or they had a medical history of antihypertensive drug use. Type 2 diabetes mellitus was defined as a fasting blood glucose ≥126 mg/dL or a medical history of hypoglycemia or insulin use. Subjects who had smoked more than 100 cigarettes in their life were categorized as smokers, while current alcohol consumption was defined as consumption of more than one glass of alcohol in the last year. Planned, systematic, and repeated physical activity to improve or maintain physical strength was considered regular exercise. Income status was classified into five categories: <1 000 000 Korean Won/month, ≥1 000 000 and <2 000 000, ≥2 000 000 and <3 000 000, ≥3 000 000 and <4 000 000, and ≥4 000 000. Education level was classified into five categories: none (did not complete elementary school), only through elementary school, only through middle school, only through high school, and through college.

Statistical analysis

Chi-square tests and t-tests were used to assess differences in anthropometric features, laboratory test results, personal medical history, and health behaviors between participants with and without chronic hepatitis B. Logistic regression analysis was used to investigate the association between chronic hepatitis B and metabolic syndrome. Logistic regression analysis was also used to investigate the associations between chronic hepatitis B and the five components of metabolic syndrome, including elevated triglycerides, elevated blood pressure, elevated blood glucose, low HDL cholesterol, and increased waist circumference. SPSS software version 11.0 (SPSS, Inc., Chicago, IL, USA) was used for analysis. P-values <0.05 were considered statistically significant.

RESULTS

Baseline characteristics of participants

A total of 5108 participants were analyzed, consisting of 2144 men and 2964 women (Table 1). Mean ± standard deviation age was 47.1 ± 15.1 years. The prevalences of HBsAg positivity and metabolic syndrome were 4.1% and 26.7%, respectively. Of the 107 men participants who were HBsAg-positive, 23.4% also had metabolic syndrome. Of the 2037 men participants who were HBsAg-negative, 31.5% had metabolic syndrome. There was no significant difference in the prevalence of metabolic syndrome between HBsAg-positive and HBsAg-negative men (P = 0.077). Of the five components of metabolic syndrome, only prevalence of elevated triglycerides was significantly lower in HBsAg-positive men than in HBsAg-negative men (29.0% vs. 38.5%, P = 0.047). Of the 102 woman participants who were HBsAg-positive, 18.6% had metabolic syndrome. Of the 2862 woman participants who were HBsAg-negative, 23.7% had metabolic syndrome. There was no significant difference in the prevalence of metabolic syndrome between HBsAg-positive and HBsAg-negative women (P = 0.233). Of the five components of metabolic syndrome, only prevalence of elevated triglycerides was significantly lower in HBsAg-positive women than in HBsAg-negative women (8.8% vs. 20.7%, P = 0.003).
Table 1.

Baseline characteristics of all participants (n = 5108)

VariableAll(n = 5108)MenWomen


HBsAg Positive(n = 107)HBsAg Negative(n = 2037)PHBsAg Positive(n = 102)HBsAg Negative(n = 2862)P
Age (year)a47.1 (15.1)45.4 (12.5)47.4 (14.6)0.11246.6 (13.5)46.9 (15.5)0.855
Gender (men), n (%)2144 (42.0%)  
Location (large city), n (%)2201 (43.1%)42 (39.3%)696 (34.2%)0.31334 (33.3%)963 (33.6%)0.710
 
BMI (kg/m2)a23.7 (3.3)24.2 (3.0)24.0 (3.1)0.46624.0 (3.7)23.5 (3.4)0.170
Systolic pressure (mm Hg)a119.1 (17.8)119.6 (13.0)123.0 (16.2)0.011118.7 (19.6)116.3 (18.5)0.201
Diastolic pressure (mm Hg)a77.3 (10.7)79.2 (9.5)80.9 (10.4)0.10675.7 (10.1)74.7 (10.3)0.328
Waist circumference (cm)a81.0 (9.7)84.6 (8.4)84.3 (8.8)0.79079.5 (9.3)78.5 (9.6)0.263
 
AST (IU/L)b22.0 [19.0–27.0]27.0 [22.0–39.0]24.0 [20.0–29.0]0.000d23.0 [20.8–29.0]20.0 [17.0–24.0]<0.0001d
ALT (IU/L)b18.0 [13.0–25.0]30.0 [21.0–47.0]22.0 [17.0–31.0]<0.0001d18.0 [15.0–23.3]15.0 [12.0–20.0]<0.0001d
Fasting blood glucose (mg/dL)b90.0 [85.0–98.0]91.0 [85.0–99.0]92.0 [86.5–101.0]0.331d88.0 [83.0–96.3]89.0 [84.0–96.0]0.600d
Total cholesterol (mg/dL)b183.0 [160.0–206.0]179.0 [153.0–199.0]184.0 [161.0–206.0]0.050d181.5 [156.0–201.3]182.0 [160.0–206.0]0.320d
HDL cholesterol (mg/dL)a45.1 (10.8)43.2 (10.3)42.2 (10.1)0.33747.9 (10.6)47.1 (10.9)0.443
Triglyceride (mg/dL)b105.0 [75.0–157.0]106.0 [76.0–158.0]126.0 [88.0–188.5]0.011d84.5 [65.0–109.3]94.0 [68.0–136.0]0.014d
 
Metabolic syndrome, n (%)1364 (26.7%)25 (23.4%)641 (31.5%)0.07719 (18.6%)679 (23.7%)0.233
 Elevated triglyceride, n (%)1418 (27.8%)31 (29.0%)785 (38.5%)0.0479 (8.8%)593 (20.7%)0.003
 Elevated blood pressure, n (%)1860 (36.4%)44 (41.4%)938 (46.0%)0.31930 (29.4%)848 (29.6%)0.962
 Elevated blood glucose, n (%)1130 (22.1%)25 (23.4%)577 (28.3%)0.26616 (15.7%)512 (17.9%)0.568
 Low HDL cholesterol, n (%)2875 (56.3%)48 (44.9%)933 (45.8%)0.84963 (61.8%)1831 (64.0%)0.648
 Abdominal obesity, n (%)1306 (25.6%)29 (27.1%)539 (26.5%)0.88326 (25.5%)712 (24.9%)0.888
Hypertension, n (%)1361 (26.6%)30 (28.0%)638 (31.3%)0.47523 (22.5%)670 (23.4%)0.840
Diabetes mellitus, n (%)437 (8.6%)9 (8.4%)225 (11.0%)0.3947 (6.9%)196 (6.8%)0.995
Obesityc, n (%)1665 (32.6%)43 (40.2%)728 (35.7%)0.35033 (32.4%)861 (30.1%)0.624
 
Smoking, n (%)1934 (37.9%)83 (77.6%)1636 (80.3%)0.4883 (2.9%)212 (7.4%)0.087
Alcohol, n (%)3287 (74.9%)83 (77.6%)1743 (85.6%)0.02363 (61.8%)1938 (67.7%)0.207
Exercise, n (%)2432 (47.6%)56 (52.3%)1051 (51.6%)0.88143 (42.2%)1282 (44.8%)0.599
Income status, n (%)n = 5022n = 103n = 19990.315n = 102n = 28180.336
 <1 000 000 Won1269 (25.3%)17 (16.5%)472 (23.6%) 20 (19.6%)760 (27.0%) 
 ≥1 000 000 but <2 000 000 Won1462 (29.1%)34 (33.0%)605 (30.3%) 36 (35.3%)787 (27.0%) 
 ≥2 000 000 but <3 000 000 Won1196 (23.8%)23 (22.3%)480 (24.0%) 22 (21.6%)671 (23.8%) 
 ≥3 000 000 but <4 000 000 Won517 (10.3%)16 (15.5%)213 (10.7%) 10 (9.8%)278 (9.9%) 
 ≥4 000 000 Won578 (11.5%)13 (12.6%)229 (11.5%) 14 (13.7%)322 (11.4%) 
Education level, n (%)n = 5065n = 107n = 20180.0899928410.004
 none500 (9.9%)2 (1.9%)88 (4.4%) 11 (11.1%)399 (14.0%) 
 only through elementary school776 (15.3%)6 (5.6%)268 (13.3%) 15 (15.2%)487 (17.1%) 
 only through middle school590 (11.6%)15 (14.0%)239 (11.8%) 23 (23.2%)313 (11.0%) 
 only through high school1891 (37.3%)43 (40.2%)789 (39.1%) 35 (35.4%)1024 (36.0%) 
 through college1308 (25.8%)41 (38.3%)634 (31.4%) 15 (15.2%)618 (21.8%) 

ALT, alanine aminotransferase; AST, aspartate aminotransferase.

aData are expressed as mean (SD).

bData are expressed as median [25–75 percentiles].

cObesity was defined as body mass index ≥25 kg/m2.

dP values were obtained using Mann-Whitney U test for skewed variables: AST, ALT, fasting glucose, total cholesterol, and triglyceride.

ALT, alanine aminotransferase; AST, aspartate aminotransferase. aData are expressed as mean (SD). bData are expressed as median [25–75 percentiles]. cObesity was defined as body mass index ≥25 kg/m2. dP values were obtained using Mann-Whitney U test for skewed variables: AST, ALT, fasting glucose, total cholesterol, and triglyceride.

Serum HBsAg and metabolic syndrome

In a multivariate analysis, the odds ratio of a positive result for HBsAg was 0.612 (95% confidence interval [CI] 0.375–0.998) in men with metabolic syndrome and 0.695 (95% CI 0.400–1.208) in women with metabolic syndrome, after adjusting for age, location, smoking habits, alcohol consumption, exercise habits, income status, and education level (Table 2).
Table 2.

Multivariate analysis of the association between positive HBsAg and metabolic syndrome

ModelMen (n = 2144)Women (n = 2964)


Odds ratio95% CIP valueOdds ratio95% CIP value
Unadjusted0.6640.420–1.0490.0790.7360.444–1.2210.235
Model 1a0.6590.412–1.0540.0820.7210.416–1.2490.243
Model 2b0.6560.410–1.0490.0790.7150.413–1.2390.232
Model 3c0.6120.375–0.9980.0490.6950.400–1.2080.197

CI, confidence interval.

aAdjusted for age.

bAdjusted for age, location and exercise habits.

cAdjusted for age, location, smoking habits, alcohol consumption, exercise habits, income status, and education levels.

CI, confidence interval. aAdjusted for age. bAdjusted for age, location and exercise habits. cAdjusted for age, location, smoking habits, alcohol consumption, exercise habits, income status, and education levels. Multivariable analyses were performed to explore the associations between a positive result for HBsAg and the five components of metabolic syndrome. The odds ratio for elevated triglycerides was 0.631 in HBsAg-positive men (95% CI 0.404–0.986) and 0.343 in HBsAg-positive women (95% CI 0.170–0.693; Table 3). Elevated triglycerides were inversely associated with HBsAg positivity.
Table 3.

Multivariate analysis of the association between positive HBsAg and metabolic abnormalities

 Dependent variables

 ElevatedtriglycerideElevated bloodpressureElevated bloodglucoseLow HDLcholesterolIncreased waistcircumference
Men (n = 2144)

Positive HBsAga     
 Odds ratio0.6310.8560.8030.9151.042
 95% CI0.404–0.9860.558–1.3140.491–1.3140.608–1.3760.660–1.645
P value0.0430.4770.3820.6700.860

Women (n = 2964)

Positive HBsAga     
 Odds ratio0.3431.0370.8400.8621.014
 95% CI0.170–0.6930.623–1.7250.476–1.4830.569–1.3050.624–1.648
P value0.0030.8900.5480.4820.955

CI, confidence interval.

aAdjusted for age, location, smoking habits, alcohol consumption, exercise habits, income status, and education level.

CI, confidence interval. aAdjusted for age, location, smoking habits, alcohol consumption, exercise habits, income status, and education level.

DISCUSSION

Our study shows that serum HBsAg positivity is inversely correlated with prevalence of metabolic syndrome in Korean men but not in women. This is consistent with findings from other Asian studies.[8]–[10] A Taiwanese study reported that the prevalence of metabolic syndrome was 8.0% in HBsAg-positive subjects and 10.9% in HBsAg-negative subjects.[8] Another study performed in China reported that the prevalence of metabolic syndrome was 5.9% in HBsAg-positive participants and 8.8% in HBsAg-negative participants.[10] In both of these studies, this inverse association remained even after adjusting for age and sex. A study performed in Hong Kong reported that the prevalence of metabolic syndrome was 11.0% in patients with chronic hepatitis B and 20.2% in controls without chronic hepatitis B.[9] However, these three studies did not stratify subjects by sex, as our study did. The definition of metabolic syndrome differs according to sex, and analysis should be performed separately for men and women.[12],[13] Our study conducted separate analysis according to sex and found that only HBsAg-positive males had a lower prevalence of metabolic syndrome than their HBsAg-negative counterparts. In addition, our study used a nationally representative population, while the other studies did not. In the present study, a positive result for serum HBsAg was associated with a low prevalence of elevated triglycerides. This low prevalence might be an important contributor to the inverse association between HBsAg positivity and metabolic syndrome, which would be consistent with findings in other studies.[9] Chen et al. reported that HBsAg positivity is associated with lower prevalence of hypertriglyceridemia,[14] while Su et al. reported that chronic hepatitis B is associated with low serum levels of triglycerides.[15] However, the exact mechanism causing the low levels of triglycerides in HBsAg-positive patients remains unclear. One study suggested that the hepatitis B virus X protein is a contributor to low serum triglycerides.[16] The role of HBV in lipid metabolism should be further explored. Metabolic syndrome is related to liver fibrosis. A cross-sectional study in Taiwan reported that metabolic syndrome increases the risk of liver cirrhosis in patients with chronic hepatitis B.[17] Metabolic syndrome has been linked to increased risk and severity of liver fibrosis through activation of hepatic stellate cells.[18] However, liver cirrhosis itself can cause metabolic disturbances.[19] These observations suggest a relationship between HBV infection and diabetes mellitus; development of diabetes mellitus may contribute to secondary changes due to HBV infection but not to HBV infection itself.[20] In addition, hepatic fibrosis in an HBV-infected liver is caused by virus-induced liver injury rather than insulin resistance.[21] Thus, the cause and effect relationship between metabolic syndrome and liver cirrhosis in patients with chronic hepatitis B remains unclear.[22] Chronic hepatitis C is associated with insulin resistance, but the association between chronic hepatitis B and insulin resistance is not well-established. Huang et al. reported that chronic hepatitis B without cirrhosis is not associated with type 2 diabetes mellitus.[20] Kumar et al. reported that chronic hepatitis B is not correlated with insulin resistance.[23] On the other hand, a study using NHANES III data reported that type 2 diabetes mellitus and insulin resistance are independent predictors of overall mortality in chronic hepatitis B, although only 66 participants in the study had chronic hepatitis B.[5] Our study had several limitations. First, various conditions associated with HBsAg were not considered because the KNHANES tested only for the presence of HBsAg and hepatitis B surface antibody. An individual who is HBsAg-positive may be a healthy carrier, have chronic active hepatitis, or have liver cirrhosis. In terms of serology, HBsAg positivity is associated with various levels of HBV DNA concentration and two states of hepatitis B e antigen. Further stratification of HBsAg states should be performed to determine the exact role of HBsAg in the development of metabolic syndrome. Second, the KNHANES did not differentiate between liver cirrhosis and chronic hepatitis. Liver cirrhosis is closely related to glucose intolerance, regardless of its cause.[19] Diabetes may develop as a complication of cirrhosis, which is called hepatogenous diabetes.[24] Therefore, liver cirrhosis may have contributed to the metabolic derangement observed in our study. In addition, two recent studies reported conflicting results on the association between metabolic syndrome and liver cirrhosis in chronic hepatitis B patients.[17],[21] One of these studies reported that metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B patients.[17] However, the other reported that hepatic fibrosis in HBV-infected liver is caused by virus-induced liver injury, rather than by insulin resistance.[21] The data suggest that metabolic syndrome is not a risk factor for liver cirrhosis but an outcome of liver cirrhosis.[21] Therefore, liver cirrhosis must be excluded when clarifying the effect of HBsAg on metabolic syndrome. Third, our study was a cross-sectional study, and therefore it was not possible to explore a causal relationship between chronic HBV infection and metabolic syndrome. It is unclear whether chronic HBV infection suppresses development of metabolic syndrome. In addition, horizontal transmission could not be completely excluded from subjects with chronic infection resulting from vertical transmission; in this situation, chronic hepatitis B infection could have been followed by development of metabolic syndrome. In conclusion, data from KNHANES III indicate that HBsAg positivity is associated with a low prevalence of metabolic syndrome in men, and this association may be partly attributed to low prevalence of elevated triglycerides.
  23 in total

1.  A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10).

Authors:  C-F Jan; C-J Chen; Y-H Chiu; L-S Chen; H-M Wu; C-C Huang; M-F Yen; T H-H Chen
Journal:  Int J Obes (Lond)       Date:  2006-05       Impact factor: 5.095

2.  Association of metabolic syndrome and hepatitis B infection in a Chinese population.

Authors:  Benyan Luo; Yanwen Wang; Kang Wang
Journal:  Clin Chim Acta       Date:  2007-01-18       Impact factor: 3.786

3.  Appropriate waist circumference cutoff points for central obesity in Korean adults.

Authors:  Sang Yeoup Lee; Hye Soon Park; Dae Jung Kim; Jee Hye Han; Seon Mee Kim; Guem Joo Cho; Dae Young Kim; Hyuk Sang Kwon; Sung Rae Kim; Chang Beom Lee; Seung Joon Oh; Cheol Young Park; Hyung Joon Yoo
Journal:  Diabetes Res Clin Pract       Date:  2006-06-02       Impact factor: 5.602

4.  Socioeconomic inequalities in completion of hepatitis B vaccine series among Korean women: results from a nationwide interview survey.

Authors:  Boyoung Park; Kui Son Choi; Hoo-Yeon Lee; Jae Kwan Jun; Eun-Cheol Park
Journal:  Vaccine       Date:  2012-07-21       Impact factor: 3.641

Review 5.  Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management.

Authors:  Diego Garcia-Compean; Joel Omar Jaquez-Quintana; Jose Alberto Gonzalez-Gonzalez; Hector Maldonado-Garza
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

6.  Clinical implications of hepatogenous diabetes in liver cirrhosis.

Authors:  Andreas Holstein; S Hinze; E Thiessen; A Plaschke; E-H Egberts
Journal:  J Gastroenterol Hepatol       Date:  2002-06       Impact factor: 4.029

7.  Insulin resistance in chronic hepatitis B virus infection.

Authors:  Manoj Kumar; Ajay Choudhury; Nitin Manglik; Syed Hissar; Archana Rastogi; Puja Sakhuja; Shiv K Sarin
Journal:  Am J Gastroenterol       Date:  2009-01       Impact factor: 10.864

8.  Chronic hepatitis B virus infection and dyslipidemia.

Authors:  Ta-Chen Su; Yuan-Teh Lee; Tsun-Jen Cheng; Hsu-Ping Chien; Jung-Der Wang
Journal:  J Formos Med Assoc       Date:  2004-04       Impact factor: 3.282

9.  Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B.

Authors:  G L-H Wong; V W-S Wong; P C-L Choi; A W-H Chan; A M-L Chim; K K-L Yiu; H-Y Chan; F K-L Chan; J J-Y Sung; H L-Y Chan
Journal:  Gut       Date:  2008-10-02       Impact factor: 23.059

10.  The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III.

Authors:  Sung-Koo Kang; Tae-Wook Chung; Ji-Young Lee; Young-Choon Lee; Richard E Morton; Cheorl-Ho Kim
Journal:  J Biol Chem       Date:  2004-04-29       Impact factor: 5.157

View more
  8 in total

Review 1.  Association between hepatitis B and metabolic syndrome: Current state of the art.

Authors:  Peter Jarcuska; Sylvia Drazilova; Jan Fedacko; Daniel Pella; Martin Janicko
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

2.  Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B.

Authors:  Mandana Khalili; Margaret C Shuhart; Manuel Lombardero; Jordan J Feld; David E Kleiner; Raymond T Chung; Norah A Terrault; Mauricio Lisker-Melman; Arun Sanyal; Anna S Lok
Journal:  Diabetes Care       Date:  2018-03-29       Impact factor: 19.112

3.  Association between chronic hepatitis B infection and metabolic syndrome.

Authors:  Xiaohui Zhao; Drishti Shah; Usha Sambamoorthi
Journal:  J Diabetes Metab Disord       Date:  2018-10-27

4.  Serum HBV surface antigen positivity is associated with low prevalence of metabolic syndrome: A meta-analysis.

Authors:  Yuanyuan Li; Ying Zhao; Jianping Wu
Journal:  PLoS One       Date:  2017-05-15       Impact factor: 3.240

Review 5.  Chronic hepatitis B-associated liver disease in the context of human immunodeficiency virus co-infection and underlying metabolic syndrome.

Authors:  Edina Amponsah-Dacosta; Cynthia Tamandjou Tchuem; Motswedi Anderson
Journal:  World J Virol       Date:  2020-12-15

Review 6.  Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds.

Authors:  Je-Wen Liou; Hemalatha Mani; Jui-Hung Yen
Journal:  Int J Mol Sci       Date:  2022-03-31       Impact factor: 5.923

7.  The Role of Metabolic Factors and Steatosis in Treatment-Naïve Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase.

Authors:  Hongwu Wang; Qin Ning; Yuting Diao; Danqing Hu; Xue Hu; Peng Wang; Xiaojing Wang; Xiaoping Luo
Journal:  Infect Dis Ther       Date:  2022-04-10

8.  Unawareness of Hepatitis B Virus Infection confers on Higher Rate of Metabolic Syndrome: A Community-based Study.

Authors:  Cheng-Hung Chien; Li-Wei Chen; Chih-Lang Lin; Su-Wie Chang; Yu-Chiau Shyu; Kuan-Fu Chen; Shuo-Wei Chen; Ching-Chih Hu; Chia-Ying Yu; Rong-Nan Chien
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.